Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide and Everolimus in Progressive Medullary Thyroid Cancer
NCT01625520Phase 2Completed
- Sponsor
- University of Naples Federico II
- Start
- Feb 2012
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in Medullary Thyroid Cancer (MTC), sponsored by University of Naples Federico II. Started Feb 2012; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT01625520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625520.